George Chen, MD, MBA

Dr. Chen is the Chief Medical Officer of BeiGene, a China-based oncology RnD biotech. Dr. Chen started his pharma career at Eli Lilly (IN, USA), first as a Strategy Advisor for Corporate Strategic Asset Management Group and then as a global oncology Medical Advisor managing Gemzar and Alimta global development for GI/GU indications . Dr. Chen then joined GSK as a senior director and Chief Medical/Development Officer for GSK’s Greater China region, where he successfully transformed GSK’s China Medical and Development organization, which, under Dr. Chen’s leadership, successfully completed a number pivotal studies and China NDAs resulting 6 approvals as well as a large number of global phase II/III studies in China. After completing the China assignment, Dr. Chen was appointed as a global Medicine Development Leader for GSK Oncology leading a GSK/US biotech joint development for a phase III cancer drug candidate at the US. After a successful career at GSK, Dr. Chen joined J&J Pharm R&D as a VP and Head of Compound Development Teams in Asia, where he successfully led the Resolor global development and filing from Asia. Prior to the current position, Dr. Chen was a global VP & Head of North Asia Biotech for Sanofi Global Oncology. Before joining industry, Dr. Chen was an investigator at US National Institutes of Health at Bethesda, USA. Dr. Chen received his medical degree from the Shanghai First Medical College of the Fudan University and his MBA from the Wharton School of the University of Pennsylvania. He had his post-graduate medical trainings at Shanghai Cancer Hospital and New York Medical College, respectively. Dr. Chen specializes in Oncology and Immunology. Dr. Chen publishes widely in the fields of oncology/immunology in peer-reviewed international journals. Dr. Chen is a member of American Society of Clinical Oncology.Specialties: Oncology, Clinical Development, New Product Planning, Business Development